These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19706788)

  • 1. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice.
    Barbieri F; Pattarozzi A; Gatti M; Aiello C; Quintero A; Lunardi G; Bajetto A; Ferrari A; Culler MD; Florio T
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1078-88. PubMed ID: 19706788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.
    Barbieri F; Pattarozzi A; Gatti M; Porcile C; Bajetto A; Ferrari A; Culler MD; Florio T
    Endocrinology; 2008 Sep; 149(9):4736-46. PubMed ID: 18566118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2.
    Massa A; Barbieri F; Aiello C; Iuliano R; Arena S; Pattarozzi A; Corsaro A; Villa V; Fusco A; Zona G; Spaziante R; Schettini G; Florio T
    Ann N Y Acad Sci; 2004 Dec; 1030():264-74. PubMed ID: 15659806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin and its receptor family.
    Patel YC
    Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice.
    Kaczmarek P; Singh V; Cashen DE; Yang L; Berk S; Pasternak A; Xiong Y; Shen DM; Hutchins SM; Chapman K; Wiedenmann B; Schaeffer JM; Strowski MZ
    Neurogastroenterol Motil; 2010 Feb; 22(2):204-9, e66. PubMed ID: 19754922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.
    Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P; Ouafik L; Saveanu A; Gunz G; Fina F; Dufour H; Culler MD; Moreau JP; Enjalbert A
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
    Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
    Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Bottoni A; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Taylor JE; Culler MD; Cavazzini L; degli Uberti EC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
    Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
    Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
    Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
    Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo.
    Wolff JE; Mölenkamp G; Hotfilder M; Laterra J
    Klin Padiatr; 1997; 209(4):275-7. PubMed ID: 9293462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation.
    Casnici C; Lattuada D; Crotta K; Mastrotto C; Franco P; Culler MD; Marelli O
    J Neuroimmunol; 2006 Oct; 179(1-2):9-17. PubMed ID: 16904194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
    Price A; Shi Q; Morris D; Wilcox ME; Brasher PM; Rewcastle NB; Shalinsky D; Zou H; Appelt K; Johnston RN; Yong VW; Edwards D; Forsyth P
    Clin Cancer Res; 1999 Apr; 5(4):845-54. PubMed ID: 10213221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells.
    Watt HL; Kharmate GD; Kumar U
    Cell Signal; 2009 Mar; 21(3):428-39. PubMed ID: 19070659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.